CNTX - NASDAQ

Context Therapeutics Inc.

CNTX·NASDAQ

$2.17

-10%

HealthcareBiotechnology

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$199.38M

EPS-0.3800

P/E Ratio-5.71

Earnings Date08/05/2026

cntx

Total Debt

Last Annual Value

112.06K

3-Year CAGR

27%

5-Year CAGR

-55%

10-Year CAGR

-41%

Adjust for Inflation

Context Therapeutics Inc. Competitors Analysis of Total Debt

CNTX · NASDAQ

Company	Total Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Context Therapeutics Inc. NASDAQ:CNTX	112.06K	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. NASDAQ:ORMP	825.00K	-74.8%	9.1%	N/A
Shattuck Labs, Inc. NASDAQ:STTK	1.58M	-27.8%	N/A	N/A
Agenus Inc. NASDAQ:AGEN	334.90M	53.2%	41.9%	9.9%
Cognition Therapeutics, Inc. NASDAQ:CGTX	638.00K	-19.8%	N/A	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	502.67K	-40.2%	-4.8%	N/A
Nautilus Biotechnology, Inc. NASDAQ:NAUT	30.02M	-4.6%	-0.0%	N/A
Seer, Inc. NASDAQ:SEER	23.65M	-5.8%	0.3%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	94.14M	0.6%	73.2%	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	1.51M	-17.7%	-16.5%	35.6%
Armata Pharmaceuticals, Inc. AMEX:ARMP	288.02M	33.8%	50.0%	80.1%

Context Therapeutics Inc. Fair Value Envelope

CNTX · NASDAQ

Our analysis suggests that CNTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.17, this represents a potential HIDDEN relative to our calculated worth for Context Therapeutics Inc..

HIDDEN

Intrinsic Value

Current Price: $2.17

Related Guides

Blog Categories

Continue your CNTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.